Table 4 Relationship between (A) FVC, % predicted and (B) DLCO, % predicted and mortality in enrolled IPF patients treated with pirfenidone and no-antifibrotic drugs
A) | Pirfenidone | P-value | No antifibrotic treatment | P-value |
Mortality | ||||
 No | 73.8 (52.1; 95.3) | <0.001 | 80.5 (45.7; 111.6) | 0.050 |
 Yes | 63.0 (45.9; 81.2) | 69.2 (40.6; 101.1) | ||
Decline of FVC ≥10% | ||||
6mo | ||||
 No | 71.6 (48.6; 91.6) | 0.901 | 90.6 (53.6; 121.0) | 0.057 |
 Yes | 67.5 (55.8; 89.1) | 78.2 (45.7; 106.5) | ||
12mo | ||||
 No | 74.7 (54.1; 95.4) | 0.120 | 82.0 (56.9; 121.0) | 0.237 |
 Yes | 71.6 (48.6; 95.3) | 78.3 (45.1; 107.2) | ||
18mo | ||||
 No | 72.8 (57.7; 88.2) | 0.671 | 81.6 (57.5; 117.0) | 0.501 |
 Yes | 71.6 (50.1; 97.3) | 76.5 (46.5; 119.4) | ||
24mo | Â | Â | Â | Â |
 No | 78.1 (51.3; 95.7) | 0.020 | 78.2 (46.5; 98.6) | 0.596 |
 Yes | 71.4 (49.7; 92.5) | 72.3 (45.1; 102.8) | ||
Decline of FVC ≥5% | ||||
6mo | ||||
 No | 72.1 (50.0; 93.4) | 0.494 | 86.9 (53.6; 117.0) | 0.170 |
 Yes | 71.4 (48.6; 88.8) | 76.5 (41.2; 119.4) | ||
12mo | ||||
 No | 71.3 (53.2; 97.3) | 0.557 | 81.6 (56.9; 119.4) | 0.282 |
 Yes | 72.2 (49.7; 92.3) | 73.2 (43.3; 105.0) | ||
18mo | ||||
 No | 72.0 (53.6; 98.4) | 0.242 | 81.0 (46.5; 119.4) | 0.773 |
 Yes | 71.6 (49.7; 95.3) | 78.6 (41.2; 119.9) | ||
24mo | ||||
 No | 75.2 (50.0; 95.7) | 0.209 | 80.1 (53.6; 98.6) | 0.213 |
 Yes | 72.0 (49.7; 92.5) | 70.8 (45.1; 95.2) | ||
B) | Pirfenidone | P-value | No antifibrotic treatment | P-value |
Mortality | ||||
 No | 48.1 (33.9; 73.5) | <0.001 | 38.0 (22.1; 70.4) | 0.485 |
 Yes | 40.9 (30.3; 52.1) | 41.3 (17.8; 62.0) | ||
Decline of DLCO ≥15% | ||||
6mo | ||||
 No | 55.3 (36.9; 82.6) | 0.021 | 52.2 (47.7; 56.4) | 0.264 |
 Yes | 45.9 (33.2; 71.0) | 41.4 (20.1; 65.7) | ||
12mo | ||||
 No | 49.0 (33.4; 81.0) | 0.182 | 55.7 (29.5; 71.8) | 0.108 |
 Yes | 46.0 (33.9; 71.1) | 43.6 (18.9; 65.9) | ||
18mo | ||||
 No | 59.7 (37.7; 82.6) | 0.001 | 61.3 (47.4; 71.8) | 0.046 |
 Yes | 46.4 (33.9; 72.5) | 41.4 (15.6; 63.9) | ||
24mo | ||||
 No | 61.4 (36.3; 83.7) | 0.002 | 50.6 (35.4; 67.6) | 0.247 |
 Yes | 47.0 (33.2; 69.1) | 42.4 (21.4; 65.7) | ||
Decline of DLCO ≥ 10% | ||||
6mo | ||||
 No | 56.3 (35.4; 81.0) | 0.004 | 52.2 (39.2; 60.5) | 0.077 |
 Yes | 45.8 (32.4; 67.3) | 38.6 (20.1; 65.7) | ||
12mo | ||||
 No | 51.4 (35.7; 83.7) | 0.017 | 54.3 (30.2; 69.7) | 0.147 |
 Yes | 45.8 (33.5; 66.8) | 40.4 (18.9; 65.9) | ||
18mo | ||||
 No | 56.0 (34.5; 81.0) | 0.041 | 51.8 (29.6; 71.8) | 0.223 |
 Yes | 46.5 (33.9; 72.8) | 41.4 (15.6; 63.9) | ||
24mo | ||||
 No | 55.2 (36.3; 83.7) | 0.012 | 48.6 (35.4; 67.6) | 0.108 |
 Yes | 46.9 (32.4; 67.3) | 40.1 (21.4; 63.9) | ||